
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics Inc's positive outlook is supported by the expansion of eligibility criteria for its Phase 3 HERO trial of ARD-101, lowering the age limit from 10 to 7 for patients with Prader Willi Syndrome (PWS), thereby increasing the potential patient population. Despite a revised likelihood of success at 50% and an extended potential product launch timeline to 2029, the company continues to explore additional avenues for tackling general obesity, positioning itself competitively against injectable GLP-1 therapeutics. Furthermore, the anticipation of topline data expected in Q3 2026 highlights Aardvark's proactive steps in advancing its clinical programs, which may enhance investor confidence and drive future growth.
Bears say
The analysis indicates a negative outlook for Aardvark Therapeutics's stock due to several fundamental concerns surrounding its lead product candidate, ARD-101. Key issues include potential delays in the HERO trial timeline, regulatory uncertainties, and the risk of negative clinical results, which could hinder the company's progress and market presence. Additionally, the presence of multiple risks, including competitive market pressures and possible share dilution from financing activities, contributes to a pessimistic financial perspective on the firm's future viability.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares